SABS
SAB Biotherapeutics, Inc.
$3.33
-1.48%
$254.6M
No data for this timeframe.
Vol
Market Cap$254.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders30 funds
Inst. Value$84.4M
Inst. Activity8 buys / 2 sells
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases5
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001833214·Prev Close $3.38
Recent Activity
May 29, 2026
Press
SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2026, highlighting it
Impact 3/10
May 29, 2026
fda
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully h
May 12, 2026
SEC
SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net loss widening to $18.9
PRESS-RELEASE — Impact 7/10
Mar 24, 2026
Insider
Kropotova Alexandra surrendered for taxes 988 shares
CHIEF MEDICAL OFFICER
Mar 19, 2026
Press
SAB Biotherapeutics (SABS) closed an underwritten public offering of 19,324,677 shares at $3.85 per share and pre-funded
Impact 5/10
Mar 19, 2026
SEC
SAB Biotherapeutics is conducting a public offering of 19.3 million shares of common stock and pre-funded warrants to pu
8-K — Impact 6/10
Feb 3, 2026
Insider
Kropotova Alexandra was granted 2,400,000 shares
CHIEF MEDICAL OFFICER
Feb 3, 2026
Insider
Reich Samuel J was granted 4,800,000 shares
CEO
Price Targets
$10.60
+218.3% upside
Strong Buy
Current $3.33
Low $6.00
Median $11.00
High $15.00
10 analysts
$6.00
$15.00
Analyst Ratings
7Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 22, 2026 | Citigroup | INITIATE | Buy |
| May 20, 2026 | Jefferies | INITIATE | Buy |
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 11, 2026 | Rodman & Renshaw | REITERATE | Buy → Buy |
| Apr 2, 2026 | Rodman & Renshaw | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.23 | $-0.25 — $-0.20 | 3 | |
| Next Q | $-0.24 | $-0.26 — $-0.21 | 3 | |
| Current FY | $-1.08 ▼ -260.0% | $-1.10 — $-1.06 | -34% YoY | 3 |
| Next FY | $-0.89 ▼ -170.7% | $-1.07 — $-0.54 | 17% YoY | 3 |
Latest Reports
NEUTRAL
Press
3/10
SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2026, highlighting it
May 29, 2026
BEARISH
PRESS-RELEASE
7/10
SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net loss widening to $18.9
May 12, 2026
BEARISH
8-K
6/10
SAB Biotherapeutics is conducting a public offering of 19.3 million shares of common stock and pre-funded warrants to pu
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| RA CAPITAL MANAGEMENT, L.P. | $16.9M | — |
| BALYASNY ASSET MANAGEMENT L.P. | $14.4M | DOUBLED |
| ADAGE CAPITAL PARTNERS GP, | $13.0M | NEW |
| Woodline Partners LP | $10.9M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 24, 2026 | Kropotova Alexandra | F | $0.00 |
| Feb 3, 2026 | Kropotova Alexandra | A | $0.00 |
| Feb 3, 2026 | Reich Samuel | A | $0.00 |
| Feb 3, 2026 | Bausch Christoph | A | $0.00 |
| Feb 3, 2026 | To Lucy | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
30 institutional holders with $84.4M total value (22,049,027 shares) as of 2026-Q1. Top holders: ROYAL, RA, BALYASNY. Net buying activity: 8 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 1 | $0.00 | 0.0% | — |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 4,401,500 | $16.9M | 20.0% | — |
| 3 | BALYASNY ASSET MANAGEMENT L.P. | 3,760,439 | $14.4M | 17.1% | DOUBLED +690.9% |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,405,553 | $13.0M | 15.4% | NEW |
| 5 | Woodline Partners LP | 2,851,791 | $10.9M | 12.9% | — |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2,493,737 | $9.6M | 11.3% | — |
| 7 | AMERIPRISE FINANCIAL INC | 1,476,106 | $5.7M | 6.7% | — |
| 8 | Blackstone Inc. | 860,170 | $3.3M | 3.9% | TRIM -59.9% |
| 9 | ExodusPoint Capital Management, LP | 768,627 | $2.9M | 3.5% | DOUBLED +792.6% |
| 10 | MARSHALL WACE, LLP | 463,925 | $1.8M | 2.1% | ADD +96.2% |
| 11 | HB Wealth Management, LLC | 307,500 | $1.2M | 1.4% | DOUBLED +118.6% |
| 12 | BlackRock, Inc. | 301,326 | $1.2M | 1.4% | DOUBLED +1647.9% |
| 13 | VANGUARD FIDUCIARY TRUST CO | 197,619 | $756.9K | 0.9% | — |
| 14 | TWO SIGMA INVESTMENTS, LP | 181,185 | $693.9K | 0.8% | — |
| 15 | GOLDMAN SACHS GROUP INC | 113,940 | $436.4K | 0.5% | — |
| 16 | STATE STREET CORP | 74,231 | $284.3K | 0.3% | DOUBLED +465.7% |
| 17 | Brevan Howard Capital Management LP | 59,161 | $226.6K | 0.3% | — |
| 18 | BANK OF AMERICA CORP /DE/ | 55,697 | $213.3K | 0.3% | DOUBLED +424.8% |
| 19 | COMMONWEALTH EQUITY SERVICES, LLC | 46,455 | $177.9K | 0.2% | — |
| 20 | CITADEL ADVISORS LLC | 42,900 | $164.3K | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 475,439 | 3,760,439 | +690.9% | $14.4M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 3,405,553 | — | $13.0M | 2026-Q1 |
| Blackstone Inc. | TRIM | 2,143,585 | 860,170 | -59.9% | $3.3M | 2026-Q1 |
| ExodusPoint Capital Management, LP | DOUBLED | 86,113 | 768,627 | +792.6% | $2.9M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 236,460 | 463,925 | +96.2% | $1.8M | 2026-Q1 |
| BlackRock, Inc. | DOUBLED | 17,239 | 301,326 | +1647.9% | $1.2M | 2026-Q1 |
| STATE STREET CORP | DOUBLED | 13,122 | 74,231 | +465.7% | $284.3K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 10,613 | 55,697 | +424.8% | $213.3K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 42,000 | 29,700 | -29.3% | $113.8K | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 4,262 | 11,911 | +179.5% | $45.6K | 2026-Q1 |
| VANGUARD GROUP INC | DOUBLED | 365,753 | 1,847,136 | +405.0% | $6.9M | 2025-Q4 |
| BlackRock, Inc. | DOUBLED | 6,339 | 17,239 | +172.0% | $64.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 74 | 10,613 | +14241.9% | $39.7K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 168 | 4,262 | +2436.9% | $15.9K | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 282,371 | 365,753 | +29.5% | $735.2K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 11,030 | 80,840 | +632.9% | $162.5K | 2025-Q3 |
| UBS Group AG | DOUBLED | 78 | 10,658 | +13564.1% | $18.7K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 599 | 449 | -25.0% | $610.00 | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 1,083 | 78 | -92.8% | $106.00 | 2025-Q1 |
| HB Wealth Management, LLC | DOUBLED | 108,600 | 237,400 | +118.6% | $981.7K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 97 | 64 | -34.0% | $243.00 | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 165 | 97 | -41.2% | $262.00 | 2024-Q3 |
5 unique insiders with 6 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 24, 2026 | Kropotova Alexandra | CHIEF MEDICAL OFFICER | TAX W/H | 988 | — | — |
| Feb 3, 2026 | Kropotova Alexandra | CHIEF MEDICAL OFFICER | AWARD | 2,400,000 | — | — |
| Feb 3, 2026 | Reich Samuel J | CEO | AWARD | 4,800,000 | — | — |
| Feb 3, 2026 | Bausch Christoph Lawrence | CHIEF OPERATING OFFICER | AWARD | 1,800,000 | — | — |
| Feb 3, 2026 | To Lucy | See Remarks | AWARD | 2,400,000 | — | — |
| Feb 3, 2026 | Sullivan Eddie Joe | PRESIDENT | AWARD | 3,000,000 | — | — |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 0 neutral. Avg impact: 6.5/10.
NEUTRAL
3/10
SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2
May 29, 2026
NEUTRAL
5/10
SAB Biotherapeutics (SABS) closed an underwritten public offering of 19,324,677 shares at $3.85 per
Mar 19, 2026
BEARISH
6/10
SAB Biotherapeutics (SABS) announced the pricing of a public offering, selling 19.3 million shares a
Mar 18, 2026
BEARISH
6/10
SAB Biotherapeutics (SABS) has announced the commencement of an underwritten public offering of comm
Mar 17, 2026
BULLISH
7/10
SAB Biotherapeutics released Phase 1 data for its investigational therapy SAB-142 in established typ
Mar 10, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 7 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$10.60 mean target
+218.3% upside
Strong Buy (1.00)
$6.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $3.33 |
| Target Low | $6.00 |
| Target Mean | $10.60 |
| Target Median | $11.00 |
| Target High | $15.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.23 | $-0.25 | $-0.20 | — | — | — | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.24 | $-0.26 | $-0.21 | — | — | — | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-1.08 | $-1.10 | $-1.06 | -33.9% | -260.0% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-0.89 | $-1.07 | $-0.54 | 17.3% | -170.7% | — | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.230 | |
| 7d ago | $-0.240 | +0.010 |
| 30d ago | $0.000 | -0.230 |
| 60d ago | $0.000 | -0.230 |
| 90d ago | $0.000 | -0.230 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 5 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 22, 2026 | Citigroup | INITIATE | — | Buy |
| May 20, 2026 | Jefferies | INITIATE | — | Buy |
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 11, 2026 | Rodman & Renshaw | REITERATE | Buy | Buy |
| Apr 2, 2026 | Rodman & Renshaw | INITIATE | — | Buy |
| Mar 11, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 7, 2026 | UBS | INITIATE | — | Buy |
| Dec 19, 2025 | Guggenheim | INITIATE | — | Buy |
| Dec 18, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 8, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 8, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
May 29, 2026
fda
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage
May 12, 2026
earnings
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
<p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end o
May 12, 2026
earnings_calendar
SABS Q1 2026 Earnings Scheduled — 2026-05-12
May 8, 2026
short_interest
FTD: SABS — 250,000 shares ($1.0M) failed to deliver
Settlement: 20260508, Price: $4.09, FTD Value: $1,022,500, SAB BIOTHERAPEUTICS INC COM NE
May 7, 2026
earnings_calendar
SABS Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
short_interest
FTD: SABS — 227,206 shares ($0.8M) failed to deliver
Settlement: 20260506, Price: $3.68, FTD Value: $836,118.08, SAB BIOTHERAPEUTICS INC COM NE
May 5, 2026
short_interest
FTD: SABS — 143,778 shares ($0.5M) failed to deliver
Settlement: 20260505, Price: $3.69, FTD Value: $530,540.82, SAB BIOTHERAPEUTICS INC COM NE
May 4, 2026
short_interest
FTD: SABS — 258,112 shares ($0.9M) failed to deliver
Settlement: 20260504, Price: $3.47, FTD Value: $895,648.64, SAB BIOTHERAPEUTICS INC COM NE
Mar 19, 2026
offering
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
<p>MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=QL2JkwuYoHSIcOUE
Mar 18, 2026
offering
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
<p>MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=nJC2ZkLyrp1V2UGl
Mar 17, 2026
offering
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
<p>MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=PQPz1gTDS2Rrfa3R
Mar 10, 2026
fda
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
<p align="center"><em>Results demonstrated early signals of C-peptide preservation</em></p>
Mar 9, 2026
earnings
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
<p align="center"><em>Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to
Feb 18, 2026
short_interest
FTD: SABS — 136,752 shares ($0.5M) failed to deliver
Settlement: 20260218, Price: $3.88, FTD Value: $530,597.76, SAB BIOTHERAPEUTICS INC COM NE
Feb 13, 2026
short_interest
FTD: SABS — 172,699 shares ($0.7M) failed to deliver
Settlement: 20260213, Price: $4.12, FTD Value: $711,519.88, SAB BIOTHERAPEUTICS INC COM NE